MDCX - Wutah dodolan YoY sajrone 12 wulan kepungkur Medicus Pharma Corp

Medicus Pharma Ltd. is scaling its business through the automated production of low-cost transdermal patches. Revenue volatility compared to the same period last year for the TTM, based on GURU.Markets data, reflects a growth trend where 0.00 characterizes this valuation parameter. Patents in skin cancer therapy and a strong scientific team, retained through stock option programs, ensure stability.
Ringkesan rincian data analitis Medicus Pharma Ltd (MDCX)

Medicus Pharma Ltd. focuses on dermatological oncology, leveraging a stable team of leading researchers. The rolling year revenue dynamics with daily calculations provide an objective real-time assessment of the commercial efficiency of this scientific foundation. By analyzing the current YoY revenue growth rate via TTM, an investor sees a smoothed sales trend devoid of random market noise. This metric confirms the company's ability to monetize clinical trial results. The stable trend indicates high fundamental business resilience.